Viabestbuys Pharmacy Guide - Page 2

DOACs like apixaban and rivaroxaban are safe and effective for obese patients at standard doses. Dabigatran increases bleeding risk, and edoxaban may need caution in extreme obesity. Learn what works, what doesn’t, and what guidelines say.

Understanding what manufacturing changes trigger FDA re-evaluation for generic drugs is key to ensuring drug safety and availability. Major changes like facility transfers, new suppliers, or process upgrades require full review - but new programs are speeding up approvals for U.S.-made generics.

Combining warfarin with NSAIDs doubles your risk of dangerous bleeding. Learn why naproxen and ibuprofen are especially risky, what alternatives actually work, and how to protect yourself from life-threatening side effects.

Mail-order generics offer home delivery of medications but come with hidden risks like temperature damage and pricing markups. Learn how to use them safely for chronic conditions while avoiding common pitfalls.

Exploring the risks and challenges of generic cyclosporine and tacrolimus for transplant patients. Learn why bioequivalence issues, dosing differences, and switching protocols matter for safety and effectiveness.

Learn how to cut prescription costs during Medicare Part D’s donut hole in 2024 before the $2,000 out-of-pocket cap eliminates it in 2025. Proven strategies for saving hundreds or thousands on meds.

SGLT2 inhibitors help lower blood sugar and protect the heart and kidneys in type 2 diabetes, but come with risks like yeast infections and rare but serious ketoacidosis. Know who benefits most and what to watch for.

Salt substitutes with potassium chloride can cause dangerous potassium buildup when taken with ACE inhibitors or ARBs, especially for people with kidney disease. Learn who’s at risk and what safer alternatives exist.

Most people who think they're allergic to penicillin aren't. Learn how true drug allergies work, why NSAID reactions are different, and how desensitization can save lives when no other options exist.

Cognitive decline screening has evolved beyond paper tests. In 2026, digital tools and blood biomarkers now detect Mild Cognitive Impairment earlier than ever - crucial for new Alzheimer’s treatments. Here’s what works, what’s next, and how to ask for it.